| Basics |
Denali Therapeutics Inc.
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
|
| IPO Date: |
December 8, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.93B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.78 | 2.75%
|
| Avg Daily Range (30 D): |
$0.44 | 2.56%
|
| Avg Daily Range (90 D): |
$0.38 | 2.46%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
1.19M |
| Avg Daily Volume (90 D): |
1.51M |
| Trade Size |
| Avg Trade Size (Sh.): |
69 |
| Avg Trade Size (Sh.) (30 D): |
63 |
| Avg Trade Size (Sh.) (90 D): |
80 |
| Institutional Trades |
| Total Inst.Trades: |
3,331 |
| Avg Inst. Trade: |
$2.75M |
| Avg Inst. Trade (30 D): |
$2.81M |
| Avg Inst. Trade (90 D): |
$2.77M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.77M |
| Avg Closing Trade (30 D): |
$3.74M |
| Avg Closing Trade (90 D): |
$3.72M |
| Avg Closing Volume: |
140.46K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.74
|
$-.72
|
|
Diluted EPS
|
|
$-.74
|
$-.72
|
|
Revenue
|
$
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -126.9M
|
$ -124.12M
|
|
Operating Income / Loss
|
$
|
$ -137.43M
|
$ -134.96M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -50.24M
|
$ 84.26M
|
|
PE Ratio
|
|
|
|
|
|
|
